Laron syndrome: Typical and atypical forms

Kathryn (Katie) Woods, M. O. Savage

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Since the original description of LS by Laron in 1966, this rare condition has continued to assume an importance far beyond the number of affected cases as a unique model of GHR dysfunction. Recently, the potential of therapy with recombinant IGF-I has led to the recruitment and detailed study of patients from a heterogeneous genetic and geographical background and the realization that hereditary GH resistance is itself a heterogeneous condition, with considerable variation in clinical, biochemical and molecular features between patients. For the scientist, further study of the 'atypical' LS patient may lead to important insights into the signalling pathway between GH and IGF-I. For the clinician, the challenge lies in establishing the contribution of inherited forms of GH resistance to the group of children with idiopathic short stature, with the potential of offering therapy to these patients based on an understanding of the aetiological basis of their disorder.

Original languageEnglish (US)
Pages (from-to)371-387
Number of pages17
JournalBailliere's Clinical Endocrinology and Metabolism
Volume10
Issue number3
DOIs
StatePublished - 1996
Externally publishedYes

Fingerprint

Laron Syndrome
Insulin-Like Growth Factor I
Therapeutics

ASJC Scopus subject areas

  • Endocrinology
  • Biochemistry

Cite this

Laron syndrome : Typical and atypical forms. / Woods, Kathryn (Katie); Savage, M. O.

In: Bailliere's Clinical Endocrinology and Metabolism, Vol. 10, No. 3, 1996, p. 371-387.

Research output: Contribution to journalArticle

@article{639cf82ad0bc4775856b87b53bc51548,
title = "Laron syndrome: Typical and atypical forms",
abstract = "Since the original description of LS by Laron in 1966, this rare condition has continued to assume an importance far beyond the number of affected cases as a unique model of GHR dysfunction. Recently, the potential of therapy with recombinant IGF-I has led to the recruitment and detailed study of patients from a heterogeneous genetic and geographical background and the realization that hereditary GH resistance is itself a heterogeneous condition, with considerable variation in clinical, biochemical and molecular features between patients. For the scientist, further study of the 'atypical' LS patient may lead to important insights into the signalling pathway between GH and IGF-I. For the clinician, the challenge lies in establishing the contribution of inherited forms of GH resistance to the group of children with idiopathic short stature, with the potential of offering therapy to these patients based on an understanding of the aetiological basis of their disorder.",
author = "Woods, {Kathryn (Katie)} and Savage, {M. O.}",
year = "1996",
doi = "10.1016/S0950-351X(96)80500-3",
language = "English (US)",
volume = "10",
pages = "371--387",
journal = "Bailliere's Clinical Endocrinology and Metabolism",
issn = "0950-351X",
publisher = "Bailliere Tindall Ltd",
number = "3",

}

TY - JOUR

T1 - Laron syndrome

T2 - Typical and atypical forms

AU - Woods, Kathryn (Katie)

AU - Savage, M. O.

PY - 1996

Y1 - 1996

N2 - Since the original description of LS by Laron in 1966, this rare condition has continued to assume an importance far beyond the number of affected cases as a unique model of GHR dysfunction. Recently, the potential of therapy with recombinant IGF-I has led to the recruitment and detailed study of patients from a heterogeneous genetic and geographical background and the realization that hereditary GH resistance is itself a heterogeneous condition, with considerable variation in clinical, biochemical and molecular features between patients. For the scientist, further study of the 'atypical' LS patient may lead to important insights into the signalling pathway between GH and IGF-I. For the clinician, the challenge lies in establishing the contribution of inherited forms of GH resistance to the group of children with idiopathic short stature, with the potential of offering therapy to these patients based on an understanding of the aetiological basis of their disorder.

AB - Since the original description of LS by Laron in 1966, this rare condition has continued to assume an importance far beyond the number of affected cases as a unique model of GHR dysfunction. Recently, the potential of therapy with recombinant IGF-I has led to the recruitment and detailed study of patients from a heterogeneous genetic and geographical background and the realization that hereditary GH resistance is itself a heterogeneous condition, with considerable variation in clinical, biochemical and molecular features between patients. For the scientist, further study of the 'atypical' LS patient may lead to important insights into the signalling pathway between GH and IGF-I. For the clinician, the challenge lies in establishing the contribution of inherited forms of GH resistance to the group of children with idiopathic short stature, with the potential of offering therapy to these patients based on an understanding of the aetiological basis of their disorder.

UR - http://www.scopus.com/inward/record.url?scp=0029775038&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029775038&partnerID=8YFLogxK

U2 - 10.1016/S0950-351X(96)80500-3

DO - 10.1016/S0950-351X(96)80500-3

M3 - Article

C2 - 8853445

AN - SCOPUS:0029775038

VL - 10

SP - 371

EP - 387

JO - Bailliere's Clinical Endocrinology and Metabolism

JF - Bailliere's Clinical Endocrinology and Metabolism

SN - 0950-351X

IS - 3

ER -